Application:

In 1997, Beimaixin, produced by Taiwan Novartis Co., Ltd. with mirbeoxime as the main component, was launched in Taiwan in 1997 as an oral medicine for the prevention of heartworm and intestinal parasites in dogs and cats. It was the first application of mirbeoxime in China. Mirbe oxime has a broad-spectrum anti-parasitic effect on Chemicalbook, and has a good killing effect on internal and external parasites, especially nematodes and arthropods.

Biological activity:

MilbemycinOxime is a broad-spectrum antiparasitic drug with active action against helminths and mites.

Specifications